Skip to main content
Erschienen in: Intensive Care Medicine 6/2016

30.03.2016 | Original

Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study

verfasst von: Liesbet De Bus, Wouter Denys, Julie Catteeuw, Bram Gadeyne, Karel Vermeulen, Jerina Boelens, Geert Claeys, Jan J. De Waele, Johan Decruyenaere, Pieter O. Depuydt

Erschienen in: Intensive Care Medicine | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Antibiotic de-escalation is promoted to limit prolonged exposure to broad-spectrum antibiotics, but proof that it prevents the emergence of resistance is lacking. We evaluated determinants of antibiotic de-escalation in an attempt to assess whether the latter is associated with a lower emergence of antimicrobial resistance.

Methods

Antibiotic treatments, starting with empirical beta-lactam prescriptions, were prospectively documented during 2013 and 2014 in a tertiary intensive care unit (ICU) and categorized as continuation, de-escalation or escalation of the empirical antimicrobial treatment. Determinants of the de-escalation or escalation treatments were identified by multivariate logistic regression; the continuation category was used as the reference group. Using systematically collected diagnostic and surveillance cultures, we estimated the cumulative incidence of antimicrobial resistance following de-escalation or continuation of therapy, with adjustment for ICU discharge and death as competing risks.

Results

Of 478 anti-pseudomonal antibiotic prescriptions, 42 (9 %) were classified as escalation of the antimicrobial treatment and 121 (25 %) were classified as de-escalation, mainly through replacement of the originally prescribed antibiotics with those having a narrower spectrum. In multivariate analysis, de-escalation was associated with the identification of etiologic pathogens (p < 0.001). The duration of the antibiotic course in the ICU in de-escalated versus continued prescriptions was 8 (range 6–10) versus 5 (range 4–7) days, respectively (p < 0.001). Mortality did not differ between patients in the de-escalation and continuation categories. The cumulative incidence estimates of the emergence of resistance to the initial beta-lactam antibiotic on day 14 were 30.6 and 23.5 % for de-escalation and continuation, respectively (p = 0.22). For the selection of multi-drug resistant pathogens, these values were 23.5 (de-escalation) and 18.6 % (continuation) respectively (p = 0.35).

Conclusion

The emergence of antibiotic-resistant bacteria after exposure to anti-pseudomonal beta-lactam antibiotics was not lower following de-escalation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent J-L, Moreno R, The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228CrossRefPubMed Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent J-L, Moreno R, The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228CrossRefPubMed
2.
Zurück zum Zitat Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed
3.
Zurück zum Zitat Kollef MH (2001) Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 29(7):1473–1475CrossRefPubMed Kollef MH (2001) Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 29(7):1473–1475CrossRefPubMed
5.
Zurück zum Zitat Niederman MS (2006) De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 12:452–457CrossRefPubMed Niederman MS (2006) De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 12:452–457CrossRefPubMed
6.
Zurück zum Zitat Silva BNG, Andriolo RB, Atallah AN, Salomao R (2013) De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock (review). Cochrane Database Systematic Rev 3:CD007934 doi:10.1002/14651858 Silva BNG, Andriolo RB, Atallah AN, Salomao R (2013) De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock (review). Cochrane Database Systematic Rev 3:CD007934 doi:10.​1002/​14651858
7.
Zurück zum Zitat Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, Tacey M, Timsit JF, Leone M, Zahar JR, De Waele J, on behalf of the Working Group for Antimicrobial Use in the ICU (2015) A systematic review of the definitions, determinants and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. doi:10.1093/cid/civ1199 PubMed Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, Tacey M, Timsit JF, Leone M, Zahar JR, De Waele J, on behalf of the Working Group for Antimicrobial Use in the ICU (2015) A systematic review of the definitions, determinants and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. doi:10.​1093/​cid/​civ1199 PubMed
8.
Zurück zum Zitat Garnacho-Montero J, Escoresca-Ortega A, Fernandez-Delgado E (2015) Antibiotic de-escalation in the ICU: how is it best done? Curr Opin Infect Dis 28:193–198CrossRefPubMed Garnacho-Montero J, Escoresca-Ortega A, Fernandez-Delgado E (2015) Antibiotic de-escalation in the ICU: how is it best done? Curr Opin Infect Dis 28:193–198CrossRefPubMed
9.
Zurück zum Zitat Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40CrossRefPubMed Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40CrossRefPubMed
10.
Zurück zum Zitat Knaak E, Cavalieri SJ, Elsasser GN, Preheim LC, Gonitzke A, Destache CJ (2013) Does antibiotic de-escalation for nosocomial pneumonia impact intensive care unit length of stay? Infect Dis Clin Pract 21(3):172–176CrossRef Knaak E, Cavalieri SJ, Elsasser GN, Preheim LC, Gonitzke A, Destache CJ (2013) Does antibiotic de-escalation for nosocomial pneumonia impact intensive care unit length of stay? Infect Dis Clin Pract 21(3):172–176CrossRef
11.
Zurück zum Zitat Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K (2007) De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 33:1533–1540CrossRefPubMed Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K (2007) De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 33:1533–1540CrossRefPubMed
12.
Zurück zum Zitat Gonzalez L, Cravoisy A, Barraud D, Conrad M, Nace L, Lemarié J, Bollaert P-E, Gibot S (2013) Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care 17:R140CrossRefPubMedPubMedCentral Gonzalez L, Cravoisy A, Barraud D, Conrad M, Nace L, Lemarié J, Bollaert P-E, Gibot S (2013) Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care 17:R140CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun J-P, Berger P, Duran S, Faucher M, Blanche J-L, Saillard C, Vey N, Leone M (2014) De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results of an observational study. Intensive Care Med 40:41–49CrossRefPubMed Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun J-P, Berger P, Duran S, Faucher M, Blanche J-L, Saillard C, Vey N, Leone M (2014) De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results of an observational study. Intensive Care Med 40:41–49CrossRefPubMed
14.
Zurück zum Zitat Leone M, Bechis C, Baumstarck K, Lefrant J-Y, Albanèse J, Jaber S, Lepape A, Constantin J-M, Papazian L, Bruder N, Allaouchiche B, Bézulier K, Antonini F, Textoris J, Martin C, for the AZUREA network investigators (2014) De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40:1399–1408CrossRefPubMed Leone M, Bechis C, Baumstarck K, Lefrant J-Y, Albanèse J, Jaber S, Lepape A, Constantin J-M, Papazian L, Bruder N, Allaouchiche B, Bézulier K, Antonini F, Textoris J, Martin C, for the AZUREA network investigators (2014) De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40:1399–1408CrossRefPubMed
15.
Zurück zum Zitat Steurbaut K, Colpaert K, Gadeyne B, Depuydt P, Vosters P, Danneels C, Benoit D, Decruyenaere J, De Turck F (2012) COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU. J Med Syst 36:3765–3775CrossRefPubMed Steurbaut K, Colpaert K, Gadeyne B, Depuydt P, Vosters P, Danneels C, Benoit D, Decruyenaere J, De Turck F (2012) COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU. J Med Syst 36:3765–3775CrossRefPubMed
16.
Zurück zum Zitat De Bus L, Diet G, Gadeyne B, Leroux-Roels I, Claeys G, Steurbaut K, Benoit D, De Turck F, Decruyenaere J, Depuydt P (2014) Validity analysis of a unique infection surveillance system in the intensive care unit by analysis of a data warehouse built through a workflow-integrated software application. J Hosp Infect 87:159–164CrossRefPubMed De Bus L, Diet G, Gadeyne B, Leroux-Roels I, Claeys G, Steurbaut K, Benoit D, De Turck F, Decruyenaere J, Depuydt P (2014) Validity analysis of a unique infection surveillance system in the intensive care unit by analysis of a data warehouse built through a workflow-integrated software application. J Hosp Infect 87:159–164CrossRefPubMed
17.
Zurück zum Zitat De Bus L, Saerens L, Gadeyne B, Boelens J, Claeys G, De Waele JJ, Benoit DD, Decruyenaere J, Depuydt PO (2014) Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis. Crit Care 18:R152CrossRefPubMedPubMedCentral De Bus L, Saerens L, Gadeyne B, Boelens J, Claeys G, De Waele JJ, Benoit DD, Decruyenaere J, Depuydt PO (2014) Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis. Crit Care 18:R152CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Saag MS. Gilbert DN CH, Eliopoulos GM, Moellering RC (2012) The Sanford guide to antimicrobial therapy. 23rd edition of the Belgian/Luxembourg version 2012–2013. Antimicrobial Therapy Inc., Sperryville Saag MS. Gilbert DN CH, Eliopoulos GM, Moellering RC (2012) The Sanford guide to antimicrobial therapy. 23rd edition of the Belgian/Luxembourg version 2012–2013. Antimicrobial Therapy Inc., Sperryville
19.
Zurück zum Zitat Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed
21.
Zurück zum Zitat Andersen PK, Abildstrom SZ, Rosthoj S (2002) Competing risk as a multi-state model. Stat Methods Med Res 11:203–215CrossRefPubMed Andersen PK, Abildstrom SZ, Rosthoj S (2002) Competing risk as a multi-state model. Stat Methods Med Res 11:203–215CrossRefPubMed
22.
Zurück zum Zitat Pepe M, Mori M (1993) Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med 12(8):737–751CrossRefPubMed Pepe M, Mori M (1993) Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med 12(8):737–751CrossRefPubMed
23.
Zurück zum Zitat Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(4):1229–1235CrossRefPubMedPubMedCentral Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(4):1229–1235CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Gray RJ (1998) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1998) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
27.
Zurück zum Zitat Morel J, Casoetto J, Jospé R, Aubert G, Terrana R, Dumont A, Molliex S, Auboyer C (2010) De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 14(6):R225CrossRefPubMedPubMedCentral Morel J, Casoetto J, Jospé R, Aubert G, Terrana R, Dumont A, Molliex S, Auboyer C (2010) De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 14(6):R225CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D (2010) De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 25:641–646CrossRefPubMed De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D (2010) De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 25:641–646CrossRefPubMed
29.
Zurück zum Zitat Álvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan J-M, Quintana E, Sanz-Rodriguez C, The ADANN Study Group (2006) Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 10:R78CrossRefPubMedPubMedCentral Álvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan J-M, Quintana E, Sanz-Rodriguez C, The ADANN Study Group (2006) Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 10:R78CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat McCullough AR, Rathboneb J, Parekh S, Hoffmann TC, Del Mar CB (2015) Not in my backyard: a systematic review of clinicians’ knowledge and beliefs about antibiotic resistance. J Antimicrob Chemother 70:2465–2473CrossRefPubMed McCullough AR, Rathboneb J, Parekh S, Hoffmann TC, Del Mar CB (2015) Not in my backyard: a systematic review of clinicians’ knowledge and beliefs about antibiotic resistance. J Antimicrob Chemother 70:2465–2473CrossRefPubMed
31.
Zurück zum Zitat Joung MK, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, Sohn KM, Chung SM, Suh GY, Chung DR, Song JH, Peck KR (2011) Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 15(2):R79CrossRefPubMedPubMedCentral Joung MK, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, Sohn KM, Chung SM, Suh GY, Chung DR, Song JH, Peck KR (2011) Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 15(2):R79CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plésiat P, Andremonta A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–1495CrossRefPubMedPubMedCentral Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plésiat P, Andremonta A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–1495CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Carlier M, Roberts JA, Stove V, Verstraete AG, Lipman J, De Waele JJ (2015) A simulation study reveals lack of pharmacokinetic/pharmacodynamic target attainment in de-escalated antibiotic therapy in critically ill patients. Antimicrob Agents Chemother 59(8):4689–4694CrossRefPubMedPubMedCentral Carlier M, Roberts JA, Stove V, Verstraete AG, Lipman J, De Waele JJ (2015) A simulation study reveals lack of pharmacokinetic/pharmacodynamic target attainment in de-escalated antibiotic therapy in critically ill patients. Antimicrob Agents Chemother 59(8):4689–4694CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, Paugam-Burtz C, Brun-Buisson C, Timsit JF, De-escalation study Group (2015) Elaboration of a consensual definition of de-escalation allowing a ranking of beta-lactams. Clin Microbiol Infect 21(7):649.e1–649.e10CrossRef Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, Paugam-Burtz C, Brun-Buisson C, Timsit JF, De-escalation study Group (2015) Elaboration of a consensual definition of de-escalation allowing a ranking of beta-lactams. Clin Microbiol Infect 21(7):649.e1–649.e10CrossRef
35.
Zurück zum Zitat Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B, Samore M (2014) Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol 35(9):1103–1113CrossRefPubMedPubMedCentral Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B, Samore M (2014) Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol 35(9):1103–1113CrossRefPubMedPubMedCentral
Metadaten
Titel
Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study
verfasst von
Liesbet De Bus
Wouter Denys
Julie Catteeuw
Bram Gadeyne
Karel Vermeulen
Jerina Boelens
Geert Claeys
Jan J. De Waele
Johan Decruyenaere
Pieter O. Depuydt
Publikationsdatum
30.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 6/2016
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4301-z

Weitere Artikel der Ausgabe 6/2016

Intensive Care Medicine 6/2016 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.